

Hansjakob Furrer

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3053895/hansjakob-furrer-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

309
papers

16,277
citations

65
h-index

117
g-index

333
ext. papers

18,105
ext. citations

6.4
avg, IF

5.69
L-index

#	Paper	IF	Citations
309	Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. <i>Gastroenterology</i> , 2010 , 138, 1338-45, 1345.e1-7	13.3	956
308	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. <i>Lancet, The</i> , 1999 , 353, 863-8	40	812
307	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. <i>Lancet, The</i> , 2002 , 359, 30-6	40	575
306	Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2010 , 10, 251-61	25.5	527
305	Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1130-9	11.6	433
304	Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2007 , 7, 607-13	25.5	384
303	AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 282, 2220-6	27.4	341
302	Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 1-5	1.9	307
301	CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. <i>Archives of Internal Medicine</i> , 2003 , 163, 2187-95		284
300	Cohort profile: the Swiss HIV Cohort study. <i>International Journal of Epidemiology</i> , 2010 , 39, 1179-89	7.8	282
299	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. <i>Lancet, The</i> , 2001 , 358, 1322-7	40	280
298	Characteristics, determinants, and clinical relevance of CD4 T cell recovery to . <i>Clinical Infectious Diseases</i> , 2005 , 41, 361-72	11.6	257
297	Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. <i>New England Journal of Medicine</i> , 1999 , 340, 1301-6	59.2	235
296	Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013 , 10, e1001510	11.6	212
295	Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2007 , 45, 111-9	11.6	201
294	Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1408-16	11.6	191
293	CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. <i>Lancet, The</i> , 2006 , 368, 459-65	40	188

292	Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2005 , 41, 395-402	11.6	173
291	Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1381-6	7	163
290	Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010 , 201, 1488-97	7	145
289	Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 385-92	3.1	141
288	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2010 , 15, 413-23	1.6	134
287	A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. <i>Archives of Internal Medicine</i> , 2003 , 163, 1220-6		129
286	Discontinuation of secondary prophylaxis against <i>Pneumocystis carinii</i> pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. <i>New England Journal of Medicine</i> , 2001 , 344, 168-74	59.2	127
285	Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. <i>Aids</i> , 2017 , 31, 427-436	3.5	123
284	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 300-9	1.9	122
283	A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. <i>Journal of Infectious Diseases</i> , 2002 , 185, 1251-60	7	121
282	CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. <i>PLoS Medicine</i> , 2012 , 9, e1001194	11.6	119
281	Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. <i>Hepatology</i> , 2009 , 49, 1069-82	11.2	115
280	Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. <i>Archives of Internal Medicine</i> , 2010 , 170, 57-65		111
279	Ageing with HIV: medication use and risk for potential drug-drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2107-11	5.1	109
278	Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1312-21	11.6	107
277	Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. <i>Aids</i> , 2008 , 22, 301-6	3.5	107
276	Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. <i>PLoS Medicine</i> , 2008 , 5, e148	11.6	99
275	Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. <i>Journal of Virology</i> , 2006 , 80, 11094-104	6.6	98

274	Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. <i>Annals of Internal Medicine</i> , 2002 , 137, 239-50	8	98
273	Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2009 , 48, 659-66	11.6	96
272	Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. <i>Archives of Internal Medicine</i> , 2007 , 167, 1782-90		95
271	Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. <i>Clinical Infectious Diseases</i> , 2007 , 44, 94-102	11.6	94
270	Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. <i>Journal of Infectious Diseases</i> , 2005 , 191, 1419-26	7	92
269	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 217-30	1.9	91
268	Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. <i>PLoS Pathogens</i> , 2010 , 6, e1001123	7.6	91
267	Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1138-51	11.6	90
266	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. <i>Aids</i> , 2002 , 16, 1967-9	3.5	88
265	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 930-40	5.1	86
264	The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. <i>Journal of Infectious Diseases</i> , 2008 , 198, 864-7	7	85
263	High colonization rates of extended-spectrum β -lactamase (ESBL)-producing <i>Escherichia coli</i> in Swiss travellers to South Asia- a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. <i>BMC Infectious Diseases</i> , 2014 , 14, 528	4	84
262	Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. <i>Clinical Infectious Diseases</i> , 2010 , 50, 473-80	11.6	84
261	HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. <i>Aids</i> , 1999 , 13, 1857-62	3.5	84
260	Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 197-203	3.1	83
259	Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2008 , 197, 1685-94	7	83
258	Is it safe to discontinue primary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count. <i>Clinical Infectious Diseases</i> , 2010 , 51, 611-9	11.6	81
257	Self-Reported Non-Adherence to Antiretroviral Therapy Repeatedly assessed by Two Questions Predicts Treatment Failure in Virologically Suppressed Patients. <i>Antiviral Therapy</i> , 2008 , 13, 77-86	1.6	81

256	Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3047-53	5.9	80
255	Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. <i>Journal of Infectious Diseases</i> , 2011 , 203, 246-57	7	80
254	Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l. <i>Aids</i> , 2002 , 16, 1371-81	3.5	80
253	The incidence of AIDS-defining illnesses at a current CD4 count \geq 200 cells/ μ l in the post-combination antiretroviral therapy era. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1038-47	11.6	79
252	Tenofovir Use is associated with a Reduction in Calculated Glomerular Filtration Rates in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007 , 12, 1165-1174	1.6	75
251	Tracking a tuberculosis outbreak over 21 years: strain-specific single-nucleotide polymorphism typing combined with targeted whole-genome sequencing. <i>Journal of Infectious Diseases</i> , 2015 , 211, 1306-16	7	72
250	Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country. <i>Journal of Clinical Microbiology</i> , 2016 , 54, 1862-1870	9.7	70
249	Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 599-608	1.9	69
248	Adverse events of raltegravir and dolutegravir. <i>Aids</i> , 2017 , 31, 1853-1858	3.5	68
247	Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. <i>Aids</i> , 2003 , 17, F33-7	3.5	68
246	Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014 , 58, 285-94	11.6	67
245	Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005 , 10, 585-591	1.6	67
244	Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1402-12	11.6	65
243	Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. <i>American Journal of Medicine</i> , 1999 , 106, 371-2	2.4	65
242	Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. <i>Aids</i> , 2012 , 26, 567-75	3.5	63
241	Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. <i>Hepatology</i> , 2016 , 64, 1856-1869 ^{1,2}	11.2	61
240	HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis. <i>PLoS Genetics</i> , 2013 , 9, e1003318	6	61
239	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. <i>Aids</i> , 2003 , 17, 2237-44	3.5	61

238	The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. <i>Aids</i> , 2015 , 29, 2509-15	3.5	60
237	Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 755-64	1.9	60
236	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017 , 66, 297-303	13.4	58
235	Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013 , 13, 471	4	58
234	Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1454-8	7	57
233	Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, 494-9	3.1	57
232	Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv046	1	55
231	Orosomuroid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 307-18	6.1	55
230	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015 , 20,	19.8	55
229	Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. <i>Aids</i> , 2000 , 14, 243-9	3.5	54
228	Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. <i>Lancet, The</i> , 2000 , 355, 2217-8	4.0	54
227	Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2011 , 53, 1446-54	11.2	53
226	Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. <i>Clinical Infectious Diseases</i> , 2012 , 54, 1364-72	11.6	53
225	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , 2009 , 50, 1017-29	11.2	50
224	Hypogonadism in HIV-1-Infected Men is common and does not resolve during antiretroviral therapy. <i>Antiviral Therapy</i> , 2007 , 12, 261-266	1.6	50
223	Emergence of Klebsiella pneumoniae co-producing NDM-1, OXA-48, CTX-M-15, CMY-16, QnrA and ArmA in Switzerland. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 260-2	14.3	49
222	Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. <i>The Cochrane Library</i> , 2015 , CD006150	5.2	49
221	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015 , 212, 28-38	7	49

220	Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. <i>Aids</i> , 2008 , 22, 1019-28	3.5	49
219	Adjunctive corticosteroids for <i>Pneumocystis jiroveci</i> pneumonia in patients with HIV-infection. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD006150		48
218	Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. <i>Aids</i> , 2015 , 29, 2195-200	3.5	47
217	Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1659-66	5.6	46
216	Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern. <i>Aids</i> , 2017 , 31, 61-70	3.5	46
215	A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. <i>Statistics in Medicine</i> , 2010 , 29, 2757-68	2.3	45
214	Stable virulence levels in the HIV epidemic of Switzerland over two decades. <i>Aids</i> , 2006 , 20, 889-94	3.5	45
213	Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007 , 12, 1165-73	1.6	44
212	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 62, 115-122	11.6	43
211	Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. <i>Lancet HIV,the</i> , 2016 , 3, e120-31	7.8	42
210	Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. <i>Blood</i> , 2004 , 104, 1784-92	2.2	42
209	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. <i>Lancet HIV,the</i> , 2015 , 2, e335-43	7.8	41
208	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015 , 18, 20317	5.4	41
207	Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009 , 48, 979-87	11.6	41
206	Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study. <i>Aids</i> , 2010 , 24, 1907-16	3.5	41
205	CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1093-101	11.6	41
204	Infrequent Transmission of HIV-1 Drug-Resistant Variants. <i>Antiviral Therapy</i> , 2004 , 9, 375-384	1.6	40
203	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1310-1317	11.6	39

202	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. <i>Gut</i> , 2010 , 59, 1252-8	19.2	39
201	Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. <i>Aids</i> , 2011 , 25, 2149-55	3.5	39
200	Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. <i>BMJ, The</i> , 2004 , 328, 15	5.9	38
199	Survival in HIV infection: do sex and category of transmission matter? Swiss HIV Cohort Study. <i>Aids</i> , 1994 , 8, 1307-13	3.5	38
198	In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical <i>Neisseria gonorrhoeae</i> isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1605-11	5.9	37
197	<i>Mycobacterium tuberculosis</i> transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 388-95	9.7	37
196	Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-alpha plus ribavirin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 38, 238-40	3.1	36
195	Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. <i>Aids</i> , 2002 , 16, 747-55	3.5	36
194	Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. <i>Aids</i> , 2008 , 22, 767-75	3.5	35
193	Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2013 , 8, e77691	3.7	35
192	The IFNL3/4 Δ variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. <i>Aids</i> , 2014 , 28, 1885-9	3.5	34
191	Late Presentation of HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2007 , 12, 841-851	1.6	34
190	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. <i>Aids</i> , 2009 , 23, 2199-208	3.5	33
189	Effect of tenofovir on renal glomerular and tubular function. <i>Aids</i> , 2007 , 21, 1483-5	3.5	33
188	Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. <i>Aids</i> , 2001 , 15, 1793-800	3.5	33
187	A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function. <i>Clinical Nephrology</i> , 2012 , 77, 311-20	2.1	33
186	Characterization of <i>Neisseria gonorrhoeae</i> isolates detected in Switzerland (1998-2012): emergence of multidrug-resistant clones less susceptible to cephalosporins. <i>BMC Infectious Diseases</i> , 2014 , 14, 106	4	32
185	Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. <i>Circulation: Cardiovascular Genetics</i> , 2009 , 2, 621-8		32

184	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2009 , 14, 349-357	1.6	32
183	Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 68, 568-77	3.1	31
182	Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1102-12	7	30
181	Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. <i>Aids</i> , 2011 , 25, 441-51	3.5	30
180	Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. <i>Clinical Infectious Diseases</i> , 2012 , 54, 131-40	11.6	30
179	Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. <i>Aids</i> , 2009 , 23, 2485-95	3.5	30
178	Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study. <i>PLoS ONE</i> , 2017 , 12, e0172089	3.7	30
177	Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1299-309	11.6	29
176	Adjunctive corticosteroids for <i>Pneumocystis jiroveci</i> pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. <i>BMC Infectious Diseases</i> , 2005 , 5, 101	4	29
175	Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. <i>Cancer</i> , 2015 , 121, 423-31	6.4	28
174	Burden of serious fungal infections in Tanzania. <i>Mycoses</i> , 2015 , 58 Suppl 5, 70-9	5.2	27
173	Emergence of extensively drug-resistant <i>Haemophilus parainfluenzae</i> in Switzerland. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2867-9	5.9	27
172	Dog bite injuries: primary and secondary emergency department presentations--a retrospective cohort study. <i>Scientific World Journal, The</i> , 2013 , 2013, 393176	2.2	27
171	Herpes simplex virus hepatitis 4 years after liver transplantation. <i>Journal of Gastroenterology</i> , 2003 , 38, 1005-8	6.9	27
170	Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. <i>Swiss Medical Weekly</i> , 2016 , 146, w14348	3.1	27
169	Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2363-8	5.9	26
168	Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2015 , 20, 165-75	1.6	26
167	Increases in Condomless Sex in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv077		26

166	Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes. <i>Archives of Internal Medicine</i> , 2012 , 172, 1313-21		26
165	Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. <i>Antiviral Therapy</i> , 2008 , 13, 77-85	1.6	26
164	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. <i>European Respiratory Journal</i> , 2014 , 43, 166-77	13.6	25
163	Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. <i>BMC Infectious Diseases</i> , 2011 , 11, 319	4	25
162	Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 79-85	3.1	25
161	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , 2005 , 19, 1987-94	3.5	25
160	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 9-18	1.9	25
159	Multiplex Real-Time PCR Assay with High-Resolution Melting Analysis for Characterization of Antimicrobial Resistance in <i>Neisseria gonorrhoeae</i> . <i>Journal of Clinical Microbiology</i> , 2016 , 54, 2074-81	9.7	25
158	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. <i>Genetics in Medicine</i> , 2016 , 18, 814-22	8.1	25
157	HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1921-5	11.6	24
156	Late presentation of HIV-infected individuals. <i>Antiviral Therapy</i> , 2007 , 12, 841-51	1.6	24
155	Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification. <i>Antiviral Therapy</i> , 2007 , 12, 1157-1164	1.6	24
154	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1316-1326	11.6	23
153	HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. <i>Journal of the International AIDS Society</i> , 2017 , 20, 21327	5.4	23
152	Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. <i>BMC Infectious Diseases</i> , 2011 , 11, 98	4	23
151	Risk of tuberculosis following HIV seroconversion in high-income countries. <i>Thorax</i> , 2013 , 68, 207-13	7.3	22
150	The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. <i>Aids</i> , 2004 , 18, 1521-7	3.5	22
149	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 758-767	8	22

148	Polyclonal Intestinal Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae upon Traveling to India. <i>Frontiers in Microbiology</i> , 2016 , 7, 1069	5.7	22
147	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2009 , 14, 349-57	1.6	22
146	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2006 , 11, 131-142	1.6	22
145	Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1090-8	11.6	21
144	Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, 135-42	3.1	21
143	HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 250-6	3.1	21
142	Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: a single center study of epidemiologic migration-specific and clinical features. <i>AIDS Patient Care and STDs</i> , 2004 , 18, 665-75	5.8	21
141	Discontinuing or withholding primary prophylaxis against <i>Mycobacterium avium</i> in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. <i>Aids</i> , 2000 , 14, 1409-12	3.5	21
140	Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania. <i>Swiss Medical Weekly</i> , 2017 , 147, w14485	3.1	21
139	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008 , 13, 1019-1028	1.6	21
138	Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe. <i>Travel Medicine and Infectious Disease</i> , 2015 , 13, 192-6	8.4	20
137	The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2013 , 18, 337-44	1.6	20
136	Discontinuation of primary prophylaxis in HIV-infected patients at high risk of <i>Pneumocystis carinii</i> pneumonia: prospective multicentre study. <i>Aids</i> , 2001 , 15, 501-7	3.5	20
135	Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007 , 12, 931-940	1.6	20
134	A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. <i>PLoS ONE</i> , 2017 , 12, e0180983	3.7	19
133	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. <i>Medicine (United States)</i> , 2016 , 95, e5094	1.8	19
132	A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. <i>PLoS ONE</i> , 2015 , 10, e0123275	3.7	19
131	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. <i>Aids</i> , 2014 , 28, 2231-9	3.5	19

130	Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 332-8	3.2	19
129	Clinical Course, Radiological Manifestations, and Outcome of <i>Pneumocystis jirovecii</i> Pneumonia in HIV Patients and Renal Transplant Recipients. <i>PLoS ONE</i> , 2016 , 11, e0164320	3.7	19
128	Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. <i>Journal of NeuroVirology</i> , 2015 , 21, 694-701	3.9	18
127	Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. <i>Tropical Medicine and International Health</i> , 2010 , 15, 567-73	2.3	18
126	Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma. <i>Ophthalmology</i> , 2003 , 110, 432-6	7.3	18
125	Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. <i>Antiviral Therapy</i> , 2007 , 12, 1157-64	1.6	18
124	CD4+ T-Cell Count Increase in HIV-1-Infected Patients with Suppressed Viral Load Within 1 year after start of antiretroviral therapy. <i>Antiviral Therapy</i> , 2007 , 12, 889-898	1.6	18
123	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. <i>International Journal of Epidemiology</i> , 2017 , 46, 797-797n	7.8	17
122	Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv026	1	17
121	The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. <i>PLoS Computational Biology</i> , 2013 , 9, e1003203	5	17
120	A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. <i>PLoS ONE</i> , 2011 , 6, e27903	3.7	16
119	Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 53, 464-71	3.1	16
118	Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. <i>PLoS ONE</i> , 2009 , 4, e8275	3.7	16
117	Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naive Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw162	1	16
116	Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 453-460	14.3	15
115	Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania. <i>International Journal of Infectious Diseases</i> , 2016 , 46, 8-10	10.5	15
114	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1245-1253	11.6	15
113	Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. <i>PLoS ONE</i> , 2012 , 7, e50307	3.7	14

112	Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy. <i>PLoS ONE</i> , 2011 , 6, e18578	3.7	14
111	Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. <i>Scientific Reports</i> , 2016 , 6, 27580	4.9	14
110	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017 , 6,	8.9	13
109	Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. <i>PLoS ONE</i> , 2015 , 10, e0145380	3.7	13
108	Yellow fever vaccination in HIV-infected patients. <i>HIV Therapy</i> , 2010 , 4, 17-26		13
107	Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 632-41	5.7	13
106	Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines. <i>Journal of Clinical Immunology</i> , 2002 , 22, 253-62	5.7	13
105	The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 71, 302-9	3.1	13
104	Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1099-1108	11.6	12
103	Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw022	1	12
102	Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class?. <i>Aids</i> , 2011 , 25, 876-8	3.5	12
101	Possible role of anti-TNF monoclonal antibodies in the treatment of <i>Mycobacterium marinum</i> infection. <i>Rheumatology</i> , 2010 , 49, 1991-3	3.9	12
100	Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. <i>Aids</i> , 2004 , 18, 2213-5	3.5	12
99	Increased risk of wasting syndrome in HIV-infected travellers: prospective multicentre study. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2001 , 95, 484-6	2	12
98	Association of syncytium-inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. <i>Aids</i> , 1998 , 12, 1341-6	3.5	12
97	Update of the Swiss guidelines on post-treatment Lyme disease syndrome. <i>Swiss Medical Weekly</i> , 2016 , 146, w14353	3.1	12
96	Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, 205-213	3.1	12
95	Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. <i>PLoS ONE</i> , 2012 , 7, e37983	3.7	11

94	Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals. <i>Antiviral Therapy</i> , 2014 , 19, 149-59	1.6	11
93	Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of <i>Pneumocystis carinii</i> pneumonia prophylaxis. <i>Clinical Infectious Diseases</i> , 2003 , 36, 917-21	11.6	11
92	Plasma leptin levels in men are not related to the development of lipodystrophy during antiretroviral therapy. <i>Aids</i> , 2005 , 19, 1837-42	3.5	11
91	CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. <i>Antiviral Therapy</i> , 2007 , 12, 889-97	1.6	11
90	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019 , 38, 2428-2446	2.3	10
89	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020 , 222, 637-645	7	10
88	No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipodystrophy. <i>Journal of Infectious Diseases</i> , 2011 , 203, 620-4	7	10
87	Specific immunotherapy in a pollen-allergic patient with human immunodeficiency virus infection. <i>World Allergy Organization Journal</i> , 2009 , 2, 57-8	5.2	10
86	Long-term safety of discontinuation of secondary prophylaxis against <i>Pneumocystis pneumonia</i> : prospective multicentre study. <i>Aids</i> , 2004 , 18, 2047-53	3.5	10
85	Prevalence and clinical significance of splenomegaly in asymptomatic human immunodeficiency virus type 1-infected adults. Swiss HIV cohort study. <i>Clinical Infectious Diseases</i> , 2000 , 30, 943-5	11.6	10
84	Intestinal colonisation with extended-spectrum cephalosporin-resistant Enterobacteriaceae in different populations in Switzerland: prevalence, risk factors and molecular features. <i>Journal of Global Antimicrobial Resistance</i> , 2018 , 12, 17-19	3.4	10
83	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017 , 4, e251-e259	7.8	9
82	In vitro susceptibility of <i>Aerococcus urinae</i> isolates to antibiotics used for uncomplicated urinary tract infection. <i>Journal of Infection</i> , 2015 , 71, 395-7	18.9	9
81	Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 891-913	4	9
80	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. <i>Clinical Infectious Diseases</i> , 2020 , 70, 297-303	11.6	9
79	In vitro activity of clinically implemented β -lactams against <i>Aerococcus urinae</i> : presence of non-susceptible isolates in Switzerland. <i>New Microbiologica</i> , 2014 , 37, 563-6	1.1	9
78	Low Current and Nadir CD4+ T-Cell Counts are Associated with Higher Hepatitis C virus RNA Levels in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008 , 13, 455-460	1.6	9
77	Intestinal colonisation with extended-spectrum cephalosporin- and colistin-resistant Enterobacteriaceae in HIV-positive individuals in Switzerland: molecular features and risk factors. <i>International Journal of Antimicrobial Agents</i> , 2017 , 49, 519-521	14.3	8

76	Prospective assessment of loss to follow-up: incidence and associated factors in a cohort of HIV-positive adults in rural Tanzania. <i>Journal of the International AIDS Society</i> , 2020 , 23, e25460	5.4	8
75	Bactericidal activity of penicillin, ceftriaxone, gentamicin and daptomycin alone and in combination against <i>Aerococcus urinae</i> . <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 271-6	14.3	8
74	Chameleons everywhere. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	8
73	Sexually transmitted infections in HIV-infected people in Switzerland: cross-sectional study. <i>PeerJ</i> , 2014 , 2, e537	3.1	8
72	Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm ³ : Findings From the Strategic Timing of Antiretroviral Therapy (START) Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 81, 10-17	3.1	8
71	Opportunistic infections: an update. <i>Journal of HIV Therapy</i> , 2002 , 7, 2-7		8
70	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. <i>Journal of Infection</i> , 2018 , 76, 44-54	18.9	7
69	Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. <i>Biometrics</i> , 2017 , 73, 294-304	1.8	7
68	TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. <i>BioMed Research International</i> , 2013 , 2013, 373601	3	7
67	Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. <i>HIV Clinical Trials</i> , 2007 , 8, 77-85		7
66	Chronic watery diarrhea due to co-infection with <i>Cryptosporidium</i> spp and <i>Cyclospora cayentanensis</i> in a Swiss AIDS patient traveling in Thailand. <i>Journal of Travel Medicine</i> , 2001 , 8, 143-5	12.9	7
65	Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study. <i>HIV Medicine</i> , 2020 , 21, 53-63	2.7	7
64	Gradual Evolution of Cefepime Resistance in an ST131 Strain Expressing a Plasmid-Encoded CMY-2 β -Lactamase. <i>Frontiers in Microbiology</i> , 2019 , 10, 1311	5.7	6
63	Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19505	5.4	6
62	Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. <i>Journal of Infectious Diseases</i> , 2013 , 207, 759-67	7	6
61	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. <i>Aids</i> , 2007 , 21, 2201-7	3.5	6
60	A case of voluntary intoxication with efavirenz and lamivudine. <i>Aids</i> , 2006 , 20, 1352-4	3.5	6
59	IL-4 polymorphism influences susceptibility to <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive patients. <i>Aids</i> , 2019 , 33, 1719-1727	3.5	6

58	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2021 ,	7.8	6
57	Does tenofovir influence efavirenz pharmacokinetics?. <i>Antiviral Therapy</i> , 2007 , 12, 115-8	1.6	6
56	Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2069-2074	5.1	5
55	Is real time PCR preferable to the direct immunofluorescence in the diagnosis of <i>Pneumocystis jirovecii</i> pneumonia in HIV-infected patients?. <i>BMC Research Notes</i> , 2020 , 13, 235	2.3	5
54	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz464 ¹		5
53	Prevalence and Evolution of Renal Impairment in People Living With HIV in Rural Tanzania. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy072	1	5
52	Immune recovery in HIV-infected patients after <i>Candida</i> esophagitis is impaired despite long-term antiretroviral therapy. <i>Aids</i> , 2016 , 30, 1923-33	3.5	5
51	Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. <i>Aids</i> , 2011 , 25, 2306-8	3.5	5
50	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi sarcoma. <i>Aids</i> , 2018 , 32, 2759-2765	3.5	5
49	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab032	1	5
48	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
47	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004 , 9, 263-274	1.6	5
46	Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. <i>Clinical Infectious Diseases</i> , 2020 , 70, 890-897	11.6	4
45	Fewer pills do not mean fewer drug-drug interactions: severe rhabdomyolysis on Elvitegravir/Cobicistat and statin treatment. <i>Aids</i> , 2018 , 32, 676-678	3.5	4
44	Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. <i>Mycoses</i> , 2019 , 62, 1127-1132	5.2	4
43	Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone. <i>HIV Clinical Trials</i> , 2014 , 15, 92-103		4
42	Effects of HIV type-1 immune selection on susceptibility to integrase inhibitor resistance. <i>Antiviral Therapy</i> , 2009 , 14, 953-64	1.6	4
41	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1352-60	5.1	3

40	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. <i>BMC Infectious Diseases</i> , 2019 , 19, 834	4	3
39	First two cases of severe multifocal infections caused by <i>Klebsiella pneumoniae</i> in Switzerland: characterization of an atypical non-K1/K2-serotype strain causing liver abscess and endocarditis. <i>Journal of Global Antimicrobial Resistance</i> , 2017 , 10, 165-170	3.4	3
38	Imaging patterns of <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive and renal transplant patients - a multicentre study. <i>Swiss Medical Weekly</i> , 2019 , 149, w20130	3.1	3
37	Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study ¹ . <i>Journal of Travel Medicine</i> , 2020 , 27,	12.9	3
36	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2134-e2141	11.6	3
35	Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, 227-232	3.1	3
34	Fatal Measles Virus Infection After Rituximab-Containing Chemotherapy in a Previously Vaccinated Patient. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy244	1	3
33	Withholding Primary <i>Pneumocystis Pneumonia</i> Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021 , 73, 195-202	11.6	2
32	Think tuberculosis-but is thinking enough?. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 639-640	25.5	2
31	Clonal analysis of <i>Aerococcus urinae</i> isolates by using the repetitive extragenic palindromic PCR (rep-PCR). <i>Journal of Infection</i> , 2016 , 72, 262-5	18.9	2
30	Awareness and management of elevated blood pressure among human immunodeficiency virus-infected adults receiving antiretroviral therapy in urban Zambia: a call to action. <i>Global Health Action</i> , 2017 , 10, 1359923	3	2
29	Management of Opportunistic Infection Prophylaxis in the Highly Active Antiretroviral Therapy Era. <i>Current Infectious Disease Reports</i> , 2002 , 4, 161-174	3.9	2
28	HIV-Infected Patients Developing Tuberculosis Disease Show Early Changes in the Immune Response to Novel Antigens. <i>Frontiers in Immunology</i> , 2021 , 12, 620622	8.4	2
27	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ μ L. <i>Journal of the International AIDS Society</i> , 2021 , 24, e25726	5.4	2
26	Dissemination of is associated to a null variant that limits antigen exchange via trafficking extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2021 , 10, e12046	16.4	2
25	The influence of human genetic variation on Epstein-Barr virus sequence diversity. <i>Scientific Reports</i> , 2021 , 11, 4586	4.9	2
24	Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant With Tigecycline Monotherapy. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz551	1	1
23	Travellers returning ill from the tropics - a descriptive retrospective study. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2016 , 2, 6	3.2	1

22	AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19621	5.4	1
21	The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19561	5.4	1
20	Reply to Hamlyn et al. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1394-1395	11.6	1
19	Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2007 , 81, 8846-8848	6.6	1
18	Importance of critical care staffing and standard intensive care therapy in the COVID-19 era: a descriptive study of the first epidemic wave at a Swiss tertiary intensive care unit. <i>Swiss Medical Weekly</i> , 2021 , 151, w20529	3.1	1
17	Increasing Frequency and Transmission of HIV-1 Non-B Subtypes among Men Who Have Sex with Men in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2021 ,	7	1
16	Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2681-2689	5.1	1
15	Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome. <i>HIV Clinical Trials</i> , 2006 , 7, 48-54		0
14	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. <i>PLoS Biology</i> , 2020 , 18, e3000963	9.7	0
13	Smartphone App and Carbon Monoxide Self-Monitoring Support for Smoking Cessation: A Randomized Controlled Trial Nested into the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 85, e8-e11	3.1	0
12	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1413-1421	11.6	0
11	SPHN/PHRT: Forming a Swiss-Wide Infrastructure for Data-Driven Sepsis Research. <i>Studies in Health Technology and Informatics</i> , 2020 , 270, 1163-1167	0.5	0
10	Inhibition of syncytia-inducing (SI) virus by autologous serum from HIV-1-infected individuals. <i>Clinical and Diagnostic Virology</i> , 1996 , 6, 127-35		
9	How do healthcare providers construe patient complexity? A qualitative study of multimorbidity in HIV outpatient clinical practice. <i>BMJ Open</i> , 2021 , 11, e051013	3	
8	HIV-Infektion 2015 , 1-15		
7	Rate of treatment success and associated factors in the program for drug-susceptible tuberculosis in the Forest Region, Republic of Guinea, 2010-2017: A real-world retrospective observational cohort study. <i>International Journal of Infectious Diseases</i> , 2021 , 110, 6-14	10.5	
6	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		
5	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV 2020 , 18, e3000963		

- 4 Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV **2020**, 18, e3000963
- 3 Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV **2020**, 18, e3000963
- 2 Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV **2020**, 18, e3000963
- 1 Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV **2020**, 18, e3000963